Oppenheimer lowered the firm’s price target on Alumis to $25 from $26 and keeps an Outperform rating on the shares following quarterly results and business update. This follows Tuesday’s news that shareholders of both Alumis (ALMS) and Acelyrin (SLRN) had approved the merger of the companies with the transaction expected to close in Q2, the firm notes.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS: